Novo Nordisk's first phase III data for weekly insulin to be released in few months
The first data from Novo Nordisk’s phase III program, which goes under the name Onwards, with once-weekly insulin Icodec will arrive within a few months, says Novo exec Martin Holst Lange at the company’s capital markets day.
by marketwire, translated by daniel pedersen
Novo Nordisk is expecting to conclude its phase III program, dubbed Onwards, with its once-weekly insulin Icodec in 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy update on Novo Nordisk's capital markets day agenda
For subscribers
